Piper Sandler Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains a Neutral rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $95 to $100.
November 01, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained a Neutral rating on Neurocrine Biosciences and raised the price target from $95 to $100.
The news is directly about Neurocrine Biosciences. Piper Sandler's decision to maintain a Neutral rating indicates that they do not expect significant changes in the stock's performance. However, the increase in price target from $95 to $100 suggests a slightly positive outlook, but not enough to change the stock's rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100